Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing

Eur J Pharm Biopharm. 2023 Mar:184:103-115. doi: 10.1016/j.ejpb.2023.01.001. Epub 2023 Jan 18.

Abstract

Teduglutide (Revestive®) is a glucagon-like peptide-2 analogue used for the treatment of short bowel syndrome, a rare life-threatening condition in which the amount of functional gut is too short to enable proper absorption of nutrients and fluids. During handling prior to administration to the patient in hospital, it is possible that peptide-based medicines may be exposed to environmental stress conditions that could affect their quality. It is therefore essential to carry out stress testing studies to evaluate how such medicines respond to these stresses. For this reason, in this paper we present a strategy for a comprehensive analytical characterization of a peptide and a stress testing study in which it was subjected to various stress conditions: heating at 40 °C and 60 °C, light exposure and shaking. Several complementary analytical techniques were used throughout this study: Far UV circular dichroism, intrinsic protein fluorescence spectroscopy, dynamic light scattering, size-exclusion chromatography and intact and peptide mapping reverse-phase chromatography coupled to mass spectrometry. To the best of our knowledge, this is the first study to offer an in-depth description of the chemical structure of teduglutide peptide and its physicochemical characteristics after stress stimuli were applied to the reconstituted medicine Revestive®.

Keywords: Physico-chemical characterization; Stress testing; Teduglutide.

MeSH terms

  • Gastrointestinal Agents
  • Glucagon-Like Peptide 2 / therapeutic use
  • Humans
  • Mass Spectrometry
  • Peptides*
  • Short Bowel Syndrome* / drug therapy

Substances

  • teduglutide
  • Peptides
  • Glucagon-Like Peptide 2
  • Gastrointestinal Agents